05/22/2012
https://www.congress.gov...
"I completely agree and support FDA finalizing its guidance on good manufacturing practices for the cosmetics industry."
"I'm not certain that the current FDA structure could provide that stability."
"Legislative solutions that incorporate all stakeholders are more transparent and could be more appropriate to ensuring oversight for high-risk tests."
"I fear that, as has been intimated, the current review process that the FDA has would not be adequate to accommodate all of the tests that fall under their definition of LDTs, and that without further..."